ATS 2018 International Conference - Mobile

Benralizumab Improves Morning Peak Expiratory Flow While Reducing Oral Corticosteroid Dosages for Patients with Severe, Uncontrolled Asthma in the ZONDA Phase III Trial [Board No. 410]

Location: Board no. 410

Session Type: RAPiD: Rapid Abstract Poster Discussion Session

Sunday

May

20

2:15 PM

4:15 PM

Speaker(s)/Author(s)

Joel N. Kline

MD
Univ of Iowa Hosp & Clinics;University of Iowa Carver College of Medicine

Njira Lugogo

MD
University of Michigan Medical Center

Frank Trudo

MD, MBA
AstraZeneca

Ian Hirsch

PhD
AstraZeneca

James G. Zangrilli

MD
AstraZeneca

Mitchell Goldman

MD, PhD
AstraZeneca

View Abstract

Benralizumab Improves Morning Peak Expiratory Flow While Reducing Oral Corticosteroid Dosages for Patients with Severe, Uncontrolled Asthma in the ZONDA Phase III Trial

Parent Sessions

A101 - MECHANISMS AND CLINICAL FEATURES OF SEVERE ASTHMA...
05-20-2018 2:15 PM - 4:15 PM